SOZO® Digital Health Platform Gets FDA Breakthrough Device Designation

SOZO® Digital Health Platform was designated a Breakthrough Device by the Food and Drug Administration (FDA) for a proposed indication of renal failure.

The news was announced today by ImpediMed Limited (ASX:IPD), a global medical technology company using bioimpedance spectroscopy (BIS) to generate powerful data to improve patient health

Using bioimpedance spectroscopy, the SOZO® Digital Health Platform aims to provide clinicians with a more precise measure of fluid volume to be removed from a renal failure patient during dialysis. The current standard-of-care method to measure the accumulation of fluid in kidney failure patients utilizes weight scales. These scales cannot account for changes in body composition, with muscle loss being a common side effect of end-stage renal disease patients. The potential for SOZO® to address this deficiency was paramount in the FDA awarding its Breakthrough Designation to the SOZO® Digital Health Platform.

The Breakthrough Device Designation is granted when a device meets several criteria, including providing for more effective treatment or diagnosis of life-threatening or irreversibly debilitating human disease or conditions.

“Dry weight assessment and appropriate fluid removal during dialysis remains a significant challenge for nephrologists. Clinical assessment alone appears to be inadequate in many dialysis patients, especially those with multiple coexisting illnesses including cardiovascular disease and diabetes. Both inadequate fluid removal and excessive fluid removal resulting in hypotension may adversely affect quality of life, increase hospitalizations and increase mortality,” noted Dr. Mark M. Boiskin, MD FACP, of the Balboa Nephrology Medical Group and California Institute of Renal Research. “A device that can quickly and easily be used in the dialysis setting to accurately measure fluid volume is currently not FDA approved and readily available. Such a device may significantly improve quality of care and improve patient outcomes.”

“We are extremely pleased to be moving forward with the renal opportunity through the FDA Breakthrough Device Program. There is a clear need for an innovative device to help clinicians more effectively manage end-stage renal disease patients. The mortality rate of these patients remains persistently high, with many dying from fluid related heart failure. We believe SOZO® can provide a significant improvement to the dialysis process by better quantifying the volume of fluid needed to be removed,” said Richard Carreon, Managing Director and CEO of ImpediMed. “It also allows us to advance the discussions with both potential clinical and commercial partners, with a goal of moving quickly to clinical trials and subsequently to commercialization.”

SourceImpediMed
Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

The Evolut ™ FX+ TAVR system leverages market-leading valve performance with addition of larger windows to facilitate coronary access
The study was an analysis of AstraZeneca’s Phase 2 52-Week clinical trial of tralokinumab in patients with Idiopathic Pulmonary Fibrosis (IPF). The patient data from the trial was processed with Brainomix’s e-Lung tool. The tool is uniquely powered by the weighted reticulovascular score (WRVS), a novel biomarker that incorporates reticular opacities and vascular structures of the lung.
“Since the algorithm for matching patients with donors is changing across for all organs, this was a prime time to better understand whether transplant team decisions to accept a donated organ varied by patient race and gender,” she said. “We wanted to understand how the process of receiving a transplant after listing varied by race and gender, and the combination of the two, so that steps can be taken to make that process more equitable," said Khadijah Breathett, MD.
The Mount Sinai study found that primary care physicians’ approach reflects a dearth of evidence-based guidance for lung cancer screening shared decision-making in patients with complex comorbidities
This is the first ever transplantation of a genetically engineered porcine kidney into a living human recipient.

By using this website you agree to accept Medical Device News Magazine Privacy Policy

Exit mobile version